Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNational Cancer Institute, Naples
About this trial
This is an observational, prospective study enrolling patients who meet the inclusion criteria and provide consent for the use of biopsy samples collected as part of standard clinical practice. The analysis will focus on the following biomarkers: TP53, P16, Cyclin D1, EGFR, Akt, PDL-1, and ERCC1.
These biomarkers will be examined in both observation groups.
Eligibility criteria
Qualifiers
Patients aged > 18 years
Written informed consent approved by the competent Independent Ethics Committee
Histopathological diagnosis of squamous cell carcinoma of the head and neck region originating from one of the following organs or structures: Oral cavity, oropharynx, larynx, hypopharynx
Locally advanced stage: from T1N1M0 to T4N3M0
Disqualifiers
Recurrent/metastatic disease
Presence of a synchronous second tumor
Trial design
Treatments tested in this trial
- Biomarkers evaluation
Treatment groups
128 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov